Introduction
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 30–38% of the European population, with steatohepatitis (MASH) driving cirrhosis and hepatocellular carcinoma.¹ Multiple incretin-based therapies have demonstrated histologic efficacy, yet no head-to-head trials exist and significant guideline discordance persists regarding patient selection and fibrosis thresholds. This creates an urgent unmet need for harmonised European guidance.
Aims & Methods
We aimed to evaluate comparative histologic efficacy of incretin-based therapies in MASH and analyse international guideline discordance to inform European practice. Phase 2b/3 RCTs, network meta-analyses, consensus reports, and guidelines (EASL-EASD-EASO, AASLD, ADA, 2026 Younossi global Delphi consensus) were reviewed through March 2026. Asian-Pacific society guidelines were also included for comparison. Recommendations were compared across treatment eligibility, fibrosis staging, cardiometabolic risk integration, and implementation feasibility.
Results
Phase 3 trials confirmed robust histologic efficacy. In ESSENCE, semaglutide 2.4 mg weekly achieved MASH resolution without fibrosis worsening in 62.9% versus 34.3% placebo (p<0.001) and fibrosis improvement in 36.8% versus 22.4% (p<0.001).² In SYNERGY-NASH, tirzepatide demonstrated dose-dependent MASH resolution (44–62% versus 10% placebo) with fibrosis improvement (51–55% versus 30%).³ Semaglutide failed to improve fibrosis in compensated cirrhosis, underpinning F2–F3 regulatory restrictions.⁴ Meta-analytic data confirmed benefits for MASH resolution (OR 3.48, 95% CI 2.69–4.51) and fibrosis regression (OR 1.79, 95% CI 1.37–2.35).⁵
A network meta-analysis of 29 RCTs (n=9,324) ranked pegozafermin (SUCRA 91.75), survodutide (SUCRA 90.87), and tirzepatide (SUCRA 84.70) highest for MASH resolution, while semaglutide ranked lower despite sole phase 3 regulatory data.⁶ This exposes a critical tension between comparative efficacy rankings and regulatory maturity, as agents with the strongest network rankings lack phase 3 confirmatory data for regulatory submission.
Guideline discordance emerged across three domains. First, EASL-EASD-EASO recommends incretin-based therapies within a weight-loss strategy before second-stage NIT evaluation, whereas AASLD mandates NIT-confirmed F2–F3 fibrosis (VCTE 8–15 kPa, ELF 9.2–10.5) before pharmacotherapy.⁴˒⁷ The 2026 Delphi consensus endorsed VCTE 10–20 kPa or ELF 9.2–11.3 as treatment-eligible thresholds.⁸ Second, European and ADA frameworks position these agents as dual cardiometabolic-hepatic therapies, while AASLD notes cardiovascular benefit in MASH remains presumptive.⁴˒⁹ Third, current approvals exclude F4 disease, leaving a guidance gap for patients receiving these agents for cardiometabolic indications. European implementation is further complicated by heterogeneity in NIT availability and reimbursement across healthcare systems.
Conclusion
Incretin-based therapies represent a paradigm shift in MASH, yet discordance between European metabolic-holistic and US fibrosis-mandatory approaches creates actionable clinical uncertainty for European hepatologists. An EASL-led European position statement integrating NIT-based staging, cardiometabolic profiling, and health-economic modelling is urgently needed to standardise patient selection and optimise equitable access across diverse European healthcare systems.
References
1. Tilg H, Moschen AR, Byrne CD, et al. MASLD in adults: a review. JAMA. 2026;335(2):163–74.
2. Sanyal AJ, Bedossa P, Engel SS, et al. Semaglutide in MASH. N Engl J Med. 2025;392(21):2089–99.
3. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for MASH with liver fibrosis. N Engl J Med. 2024;391(4):299–310.
4. Targher G, Tilg H, Byrne CD. MASLD. N Engl J Med. 2025;393(7):683–98.
5. Mantovani A, Petracca G, Csermely A, et al. GLP-1 RAs in MASH and fibrosis: meta-analysis. Liver Int. 2025;45(9):e70256.
6. Souza M, Al-Sharif L, Engel S, et al. Pharmacotherapies in MASH: network meta-analysis. Hepatology. 2025.
7. Bansal MB, Curry MP, Gawrieh S, et al. Semaglutide for MASH: AASLD guidance. Hepatology. 2025.
8. Younossi ZM, Razavizade M, Engel SS, et al. Global Delphi consensus in MASLD. Clin Gastroenterol Hepatol. 2026.
9. Cusi K, Budd J, Engel SS, et al. MASLD in diabetes: ADA consensus. Diabetes Care. 2025;48(7):1057–82.
